Drug Executives Describe Price-Setting Talks With PBMs, Investors

By John Wilkerson / December 6, 2019 at 6:17 PM
Updated Story When Inbrija was close to market, Acorda Therapeutics wanted to set the price of Parkinson’s therapy below the specialty tier monthly threshold of $670, but consultants and pharmacy benefit managers made the company set the list price at $950 per box, according to Ron Cohen, who founded Acorda and is the president and CEO of the company. “My vision was: Let’s price it at a rate where everyone wins,” Cohen said Wednesday (Dec. 4) at...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.